Skip to main content

News

Press Release
05/02/2018
Stereotaxis, Inc., the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that the Society for Cardiac Robotic Navigation (SCRN) has published a supplement in the European Journal of Pacing,...
Stereotaxis, Inc., the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that the Society for Cardiac Robotic Navigation (SCRN) has published a supplement in the European Journal of Pacing,...
Stereotaxis, Inc., the global...
05/02/2018
EP Lab Digest
Press Release
04/30/2018
LuxCath, LLC will showcase the next generation of its proprietary OmniView™ light-guided catheter ablation system at the 2018 Heart Rhythm Society (HRS) conference in Boston, May 9 to 12 at the Boston Convention Center. The OmniView...
LuxCath, LLC will showcase the next generation of its proprietary OmniView™ light-guided catheter ablation system at the 2018 Heart Rhythm Society (HRS) conference in Boston, May 9 to 12 at the Boston Convention Center. The OmniView...
LuxCath, LLC will showcase the...
04/30/2018
EP Lab Digest
Press Release
04/25/2018
Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a...
04/25/2018
EP Lab Digest
Press Release
04/18/2018
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate mesylate). Praxbind is indicated for...
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate mesylate). Praxbind is indicated for...
Boehringer Ingelheim announced...
04/18/2018
EP Lab Digest
Press Release
04/18/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it has entered a new worldwide collaboration with Bristol-Myers Squibb Company on a program to develop and commercialize Factor XIa (FXIa) inhibitors, including...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it has entered a new worldwide collaboration with Bristol-Myers Squibb Company on a program to develop and commercialize Factor XIa (FXIa) inhibitors, including...
The Janssen Pharmaceutical...
04/18/2018
EP Lab Digest
Press Release
04/18/2018
Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV),...
Cardiome Pharma Corp., a...
04/18/2018
EP Lab Digest
Press Release
04/11/2018
Murj, Inc., a healthcare technology company focused on transforming implantable cardiac device management, announced the availability of OnSite™— the industry’s first cloud-based workflow solution for in-office cardiac device...
Murj, Inc., a healthcare technology company focused on transforming implantable cardiac device management, announced the availability of OnSite™— the industry’s first cloud-based workflow solution for in-office cardiac device...
Murj, Inc., a healthcare...
04/11/2018
EP Lab Digest
Press Release
04/10/2018
Patients battling cardiovascular diseases, and even people hoping to prevent heart disease and stroke, now have easy digital access to care plans that appeal directly to their individual motivations. The American Heart Association (AHA), the...
Patients battling cardiovascular diseases, and even people hoping to prevent heart disease and stroke, now have easy digital access to care plans that appeal directly to their individual motivations. The American Heart Association (AHA), the...
Patients battling cardiovascular...
04/10/2018
EP Lab Digest
Press Release
04/10/2018
AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, announced that it had surpassed the milestone of 25 million recorded ECGs – by far the largest data set ever collected by any consumer ECG. The company also...
AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, announced that it had surpassed the milestone of 25 million recorded ECGs – by far the largest data set ever collected by any consumer ECG. The company also...
AliveCor, the leader in...
04/10/2018
EP Lab Digest
Press Release
04/09/2018
Fischer Medical has announced that the Bloom2 cardiac electrophysiology stimulator device has received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Bloom2 stimulator is a fundamental component of nearly all electrophysiology...
Fischer Medical has announced that the Bloom2 cardiac electrophysiology stimulator device has received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Bloom2 stimulator is a fundamental component of nearly all electrophysiology...
Fischer Medical has announced...
04/09/2018
EP Lab Digest